Zydus Life Q4 results: On May 17, Zydus Lifesciences reported a consolidated net profit of Rs 1,182 crore for the March quarter, a fourfold increase from the Rs 296 crore recorded in the same period last year.
The company’s revenue rose to Rs 5,533 crore, marking a 10 percent increase from the previous year, according to an exchange filing by the Ahmedabad-based pharmaceutical firm. Additionally, earnings before interest, taxes, depreciation, and amortisation (EBITDA) climbed to Rs 1,629.8 crore, up from Rs 1,257 crore, with the EBITDA margin improving to 29.5 percent from 25 percent a year ago. -Zydus Life Q4 results
The ultimate dividend per equity share, as announced by the board, is Rs 3.
Chronic therapies accounted for 41.2 percent of Zydus Lifesciences’ total India business during the year, with their contribution increasing by 360 basis points over the past three years.
The India-branded business grew faster than the market, achieving 8 percent year-on-year growth. Additionally, the FMCG sector saw a gradual recovery in demand, driven by an uptick in rural India.
During the quarter, Zydus Lifesciences launched five new products and obtained approval for 12 new products in the US market, including four tentative approvals. Over the entire fiscal year, the company filed 20 Abbreviated New Drug Applications (ANDAs), received approval for 46 new products (including five tentative approvals), and successfully launched 29 new products.
Zydus Lifesciences
Zydus Lifesciences is directing its efforts towards expanding its presence in emerging markets, particularly in the UK. The strategy involves capitalizing on the company’s diverse and specialized generics and specialty products within its global research and development portfolio. This approach aims to scale up operations effectively in the UK market.
In April, Zydus Lifesciences received an inspection report from the US Food and Drug Administration (FDA) regarding its injectable manufacturing facility located in Jarod, near Vadodara in Gujarat. The inspection concluded with the issuance of 10 observations.
Also Read: Aadhar Housing Finance shares
Originally established as Cadila Laboratories in 1952, Zydus Lifesciences has evolved over the years to become one of the leading pharmaceutical companies in India. With a strong foothold in both domestic and international markets, the company has steadily expanded its presence globally. Notably, Zydus Lifesciences has established itself as one of the top five players in the US generic market, reflecting its commitment to excellence and innovation in the pharmaceutical industry.
